Yahoo · Aug 7, 2026
Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook
Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.
GM
NASDAQ · GMAB
Genmab A/S
Healthcare · Biotechnology
$33.23
Down-$0.87 (-2.55%)
Updated Aug 30, 2026, 9:33 AM
SID Score
7.5/10
Composite research score
Smart Money
53/100
Neutral
- Market cap
- 19.89B
- P/E ratio
- 14.56
- Dividend yield
- 0.00%
- 52-week range
- $23.62 – $35.43
- Volume
- 1.52M
- Avg. volume
- 2.09M
Price performance
GMAB price history
1M range · 20 trading sessions · Daily adjusted prices
GMAB closed at $33.23 after 20 trading sessions, up 15.86% for the selected period.
- Last close
- $33.23
- Period change
- +15.86%
- Period low
- $28.68
- Period high
- $34.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $33.78 | $33.9295 | $33.115 | $33.23 | 1.52M |
| Aug 27, 2026 | $33.91 | $34.165 | $33.67 | $34.10 | 1.87M |
| Aug 26, 2026 | $33.78 | $33.90 | $33.36 | $33.75 | 3.09M |
| Aug 25, 2026 | $33.81 | $34.4699 | $33.72 | $34.36 | 2.03M |
| Aug 24, 2026 | $32.82 | $33.32 | $32.74 | $33.02 | 3.25M |
| Aug 21, 2026 | $33.36 | $33.98 | $33.28 | $33.45 | 2.54M |
| Aug 20, 2026 | $33.60 | $33.77 | $33.20 | $33.41 | 6.35M |
| Aug 19, 2026 | $33.41 | $34.185 | $33.255 | $34.11 | 3.23M |
| Aug 18, 2026 | $32.86 | $33.11 | $32.66 | $32.96 | 2.71M |
| Aug 17, 2026 | $32.31 | $32.935 | $32.28 | $32.84 | 3.43M |
| Aug 14, 2026 | $31.31 | $31.98 | $31.14 | $31.94 | 3.43M |
| Aug 13, 2026 | $31.50 | $31.55 | $30.98 | $31.34 | 4.09M |
| Aug 12, 2026 | $30.69 | $31.61 | $30.69 | $31.42 | 3.52M |
| Aug 11, 2026 | $30.91 | $30.98 | $30.52 | $30.85 | 1.59M |
| Aug 10, 2026 | $30.63 | $31.01 | $30.55 | $30.87 | 2.8M |
| Aug 7, 2026 | $31.44 | $31.79 | $30.915 | $31.25 | 3.51M |
| Aug 6, 2026 | $29.50 | $29.86 | $28.47 | $29.83 | 5.23M |
| Aug 5, 2026 | $29.46 | $29.77 | $29.21 | $29.26 | 1.4M |
| Aug 4, 2026 | $29.24 | $29.32 | $28.94 | $29.02 | 1.32M |
| Aug 3, 2026 | $28.645 | $28.72 | $28.09 | $28.68 | 1.74M |
Latest GMAB news
The latest Smart Investors Daily articles mentioning GMAB.
Stock researchCompany · Overview
GMAB research
Overview
Company profile and research snapshot.
Company profile
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $41.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 13, 2026 | JYSKE BANK | Buy | — |
| Jul 12, 2026 | TD COWEN | Hold | — |
| Jul 12, 2026 | H.C. WAINWRIGHT & CO., LLC | Buy | — |
| Jul 7, 2026 | DNB CARNEGIE | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Guggenheim Maintains Buy on Genmab, Raises Price Target to $42
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.
SeekingAlpha · Aug 7, 2026
Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript
Genmab A/S (GMAB) Q2 2026 Earnings Call August 6, 2026 12:00 PM EDTCompany ParticipantsJan van de Winkel - Co-Founder, President & CEOTahamtan Ahmadi -...
Yahoo · Aug 7, 2026
Genmab (GMAB) Q2 2026 Earnings Call Transcript
Revenue guidance raised to $4.3B–$4.5B as non-DARZALEX products drive half of growth.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
